Why N,N-dimethyltryptamine matters: unique features and therapeutic potential beyond classical psychedelics.
Cristiano Chaves, Rafael G. Dos Santos, Serdar Dursun, Massimo Tusconi, Mauro Giovanni Carta, Elisa Brietzke, Jaime E. C. Hallak
Frontiers in Psychiatry November 6, 2024 DOI: 10.3389/fpsyt.2024.1485337 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Commentary Peer reviewed |
|---|---|
| Topics | 5-MeO-DMT DMT |
| Keywords | Psychedelics Mental health treatment Pharmacology Therapeutic research |
| Citations | 11 |
| Key points | Argues that defining classical psychedelics mainly by serotonin 5-HT2A receptor activity oversimplifies DMT's pharmacology, overlooking its broader receptor interactions, lack of tolerance, and distinct subjective experiences. The authors contend that DMT, a naturally occurring tryptamine and the main component of the "wine of jurema" used in ancient Brazilian shamanic rituals, deserves recognition for these unique features. |
Abstract
The "wine of jurema", used in ancient Brazilian shamanic rituals, is rich in N,N-dimethyltryptamine (DMT), a naturally occurring tryptamine like serotonin and melatonin. Widely found in plants and animals, DMT is the main component of some botanical tisanes used for centuries as a channel of communication with the otherworld (1, 2). Despite being classified as a "classical psychedelic” (2-4), DMT’s unique effects are often overlooked due to an overemphasis on serotonin (5HT) 2A receptors as the key pharmacological feature of serotoninergic psychedelics. This simplification ignores DMT’s broader receptor interactions, lack of tolerance, and distinct subjective experiences.
Citations in the library
Cited by 7
- Rapid and sustained antidepressant effects of vaporized N,N-dimethyltryptamine: a phase 2a clinical trial in treatment-resistant depression. Neuropsychopharmacology May 1, 2025
- Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial. European Neuropsychopharmacology June 17, 2025
- How to set up a psychedelic study: Unique considerations for research involving human participants. Neuroscience & Biobehavioral Reviews July 1, 2026
- Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review Schizophrenia Research March 13, 2026
- Proliferative Effects of the Psychedelic N,N-Dimethyltryptamine (DMT) in Human Neural Stem Cells. ACS Chemical Neuroscience July 9, 2026
and 2 more in the library
Cites 79
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial Psychological Medicine June 15, 2018
- The Hallucinogen N,N -Dimethyltryptamine (DMT) Is an Endogenous Sigma-1 Receptor Regulator Science February 13, 2009
- Antidepressant effects of a single dose of ayahuasca in patients with recurrent depression: a preliminary report Brazilian Journal of Psychiatry March 1, 2015
- Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression Journal of Clinical Psychopharmacology December 11, 2015
- Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors Science February 16, 2023
and 74 more in the library